Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

Article activity feed

1. Version published to 10.1038/s41467-020-20439-y

   Jan 4, 2021
2. 

   ScreenIT

   Jun 9, 2020

   SciScore for 10.1101/2020.05.29.123810: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: All experimental work was conducted under the authority of a UK Home Office approved project licence that had been subject to local ethical review at PHE Porton Down by the Animal Welfare and Ethical Review Body (AWERB) as required by the Home Office Animals (Scientific Procedures) Act 1986.
   Randomization	Experimental Design: Before the start of the experiment animals were randomly assigned to challenge groups, to minimise bias.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	Animals: Twenty-two healthy, female ferrets (
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   Viruses …

   SciScore for 10.1101/2020.05.29.123810: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: All experimental work was conducted under the authority of a UK Home Office approved project licence that had been subject to local ethical review at PHE Porton Down by the Animal Welfare and Ethical Review Body (AWERB) as required by the Home Office Animals (Scientific Procedures) Act 1986.
   Randomization	Experimental Design: Before the start of the experiment animals were randomly assigned to challenge groups, to minimise bias.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	Animals: Twenty-two healthy, female ferrets (
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   Viruses and Cells: SARS-CoV-2 Victoria/01/202026 was generously provided by The Doherty Institute, Melbourne, Australia at P1 and passaged twice in Vero/hSLAM cells [ECACC 04091501] Whole genome sequencing was performed, on the challenge isolate, using both Nanopore and Illumina as described previously40.	Vero/hSLAM suggested: ECACC Cat# 04091501, RRID:CVCL_L037)
   Virus titre was determined by plaque assay on Vero/E6 cells [ECACC 85020206].	Vero/E6 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   SARS-CoV-2 virus plaque assay: Samples were diluted in serum-free MEM containing antibiotic/antimycotic (Life Technologies) and incubated in 24-well plates (Nunc, ThermoFisher Scientific, Loughborough, UK) with Vero E6 cell monolayers.	Vero E6 suggested: RRID:CVCL_XD71)
   Software and Algorithms
   Sentences	Resources
   Viruses and Cells: SARS-CoV-2 Victoria/01/202026 was generously provided by The Doherty Institute, Melbourne, Australia at P1 and passaged twice in Vero/hSLAM cells [ECACC 04091501] Whole genome sequencing was performed, on the challenge isolate, using both Nanopore and Illumina as described previously40.	Nanopore suggested: None

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.05.29.123810v1 on bioRxiv

   Jun 1, 2020